Clinical Trial Update: Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating evolocumab as an added lipid-lowering therapy and its impact on lipid core burden index in non-culprit vulnerable plaque after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Non-culprit Vulnerable Plaque

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Korea University Anam Hospital | Conditions: Clinical Trial, Acute Coronary Syndrome | Phase 4 | Status: UNKNOWN